FDA approves Cleviprex; Expression Genetics secures VC funds;

> The FDA has approved Cleviprex--an intravenous blood pressure drug--from The Medicines Company. Story

> Expression Genetics has completed its $12-million Series B financing. The final, $7 million portion of the financing was secured in July. The money will be used to fund the clinical development of its lead product--the cancer therapeutic EGEN-001--and to further advance its development of delivery technologies for siRNA and shRNA. Release

> Affymetrix says it will close its manufacturing facility in West Sacramento and relocate the operations to Singapore. Report

> The new execs taking control at MiddleBrook Pharmaceuticals may move the company from Maryland to Texas. Report

> Los Altos, CA-based Interkrin Therapeutics has secured $18.25 million of a 26.14 million Series C. Story

> Two drugmakers' hometown newspapers offer a rundown on the litigation they face over sales tactics: For AstraZeneca, it's allegations of improperly marketing Seroquel, and for Abbott, more claims over its pricing of the AIDS med Norvir. Report

> Analysts just can't get their minds off which drugmakers might make a deal next. The most recent suspects are Bayer and Onyx, which are partnered on the liver and kidney cancer med Nexavar. Report

> hould HIV drugs be used to prevent infection with the deadly virus? Given the fact that vaccine developers have to start all over on their anti-HIV shot, and microbicides haven't shown much promise either, prophylactic use of antiretroviral drugs seems like a logical choice. Report

> GaxoSmithKline is doing some fancy number-crunching in an attempt to get the U.K. to cover its cancer med Tyverb (sold as Tykerb in the U.S.). According to the Financial Times, GSK is working on a pioneering deal that would cap the cost of Tyverb--no matter how many patients sign on to use it. GSK report

And Finally... Overall, job prospects for new college grads are bleak, but hiring in biotechnology remains strong. Article

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.